I was asked recently if there was a meaningful analog to AI – its pervasiveness, its transformative potential, its power – in the annals of technology, and I answered with a straight face: “Yes. The Wheel. The Printing Press. Electricity. The Internet.” I truly believe AI is going to be that big, if not bigger, … Continue reading “Narrowing AI: A Useful Context for AI Innovation, Opportunity, and Investment”
Category: Seattle
Athira Taps Alder Ex-Alder Bio Exec Litton as Chief Operating Officer
Mark Litton has been appointed chief operating officer of Seattle-based Athira Pharma. Litton is the co-founder of Alder BioPharmaceuticals (NASDAQ: [[ticker:ALDR]]), and was chief business officer at that company until last July. Athira, previously known as M3 Biotechnology, is developing treatments for neurodegenerative disorders. The company is currently enrolling patients in a Phase 1b study … Continue reading “Athira Taps Alder Ex-Alder Bio Exec Litton as Chief Operating Officer”
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
The life science and healthcare worlds are vast. We often talk about impact in terms of millions of patients and billions of dollars. But these worlds can be small, too. It seems at times we’re never far removed from any one person, through their published papers, social media connections, friends, colleagues, or people they’ve mentored. … Continue reading “Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More”
Amgen, Novartis BACE Inhibitor Joins List of Failed Alzheimer’s Drugs
Amgen and Novartis are stopping work on an experimental Alzheimer’s disease drug after an early look at clinical data showed worsening cognitive function in patients. The interim results announced Thursday were part of a pre-planned review of data from two pivotal clinical trials testing the drug, umibecestat. Based on that review, Amgen (NASDAQ: [[ticker:AMGN]]) and … Continue reading “Amgen, Novartis BACE Inhibitor Joins List of Failed Alzheimer’s Drugs”
Trump Kills His Administration’s Plan to End Secret Drug Rebates
Donald Trump’s criticism of high drug prices began during the 2016 presidential campaign and continued through his presidency, perhaps most famously just before his inauguration when he said that drug companies were “getting away with murder.” This week has underlined the gap between the administration’s rhetoric and results. Most strikingly, the White House said last … Continue reading “Trump Kills His Administration’s Plan to End Secret Drug Rebates”
Record Exit Value for VC-Backed Startups Could Fuel Investment
More than a third of the companies that went public in the first half of this year were backed by venture capital. That, plus robust merger and acquisition activity, set a record for venture-backed exit value—$165.2 billion in money returned to investors—that’s already topped all other full-year totals, according to the latest VentureMonitor, the quarterly … Continue reading “Record Exit Value for VC-Backed Startups Could Fuel Investment”
Money Transfer Services Remitly Bags $135M in New Equity Funding
As larger sums of cash are remitted from first-world countries to the developing world, upstart money transfer services are competing with established businesses for a piece of the growing pie. One of the newer entrants to the international money transfer market, Seattle-based Remitly, announced this week it has raised $135 million in new equity funding. … Continue reading “Money Transfer Services Remitly Bags $135M in New Equity Funding”
Microsoft, Providence Tie-up Focuses on Cloud Tech in Healthcare
Microsoft, long known for its Windows operating system and prowess in the world of enterprise software, is among the computing and software giants companies making inroads in the healthcare industry. One of Microsoft’s (NASDAQ: [[ticker:MSFT]]) latest efforts to innovate at the intersection of technology and healthcare is a partnership with Providence St. Joseph Health aimed at developing … Continue reading “Microsoft, Providence Tie-up Focuses on Cloud Tech in Healthcare”
How Do YOU Think the Internet Will Evolve? A Sampling of Your Tweets
[Editor’s note: This is part of a series examining the internet’s first 50 years and predicting the next half century. Join Xconomy and World Frontiers Forum on July 16 for Net@50, an event exploring the internet’s past and future.] For my feature article “Special Report 2069: Predicting the Internet’s Next 50 Years,” I asked my Twitter … Continue reading “How Do YOU Think the Internet Will Evolve? A Sampling of Your Tweets”
Future of the Internet: What Scares Networking Pioneer Radia Perlman
[Editor’s note: This is part of a series examining the internet’s first 50 years and predicting the next half century. Join Xconomy and World Frontiers Forum on July 16 for Net@50, an event exploring the internet’s past and future.] Bob Metcalfe co-invented Ethernet, the communications standard still used for most local on-site networking, but Radia Perlman … Continue reading “Future of the Internet: What Scares Networking Pioneer Radia Perlman”
Why Ethernet Inventor Bob Metcalfe is an Internet Optimist
[Editor’s note: This is part of a series examining the internet’s first 50 years and predicting the next half century. Join Xconomy and World Frontiers Forum on July 16 for Net@50, an event exploring the internet’s past and future.] Right alongside Moore’s Law, which describes the exponential growth in computing power since the 1960s, there’s Metcalfe’s … Continue reading “Why Ethernet Inventor Bob Metcalfe is an Internet Optimist”
Bio Roundup: Duchenne Race, Warren v. Gottlieb, A $599 Genome & More
As we pause to celebrate the 4th of July, another birthday is top of mind: A third baby whose embryonic DNA was edited by Chinese scientist He Jiankui. As Xconomy reported in November, He hinted about a second pregnancy after his infamous revelation of twins altered with CRISPR gene editing tools. That second pregnancy—a third … Continue reading “Bio Roundup: Duchenne Race, Warren v. Gottlieb, A $599 Genome & More”
Q&A: Providence Exec on Bluetree Acquisition, Trends in Health Tech
Providence St. Joseph Health, a Renton, WA-based organization that operates 51 hospitals and 829 clinics across five US states, announced its latest strategic, IT-focused acquisition last week. The company Providence has agreed to purchase—financial terms aren’t being disclosed—is Bluetree Network, a Madison, WI-based consultancy that works with healthcare providers to install and optimize electronic health … Continue reading “Q&A: Providence Exec on Bluetree Acquisition, Trends in Health Tech”
Ex-Apple UX Guru Don Norman Calls for Replacing the Internet
[Editor’s note: This is part of a series examining the internet’s first 50 years and predicting the next half century. Join Xconomy and World Frontiers Forum on July 16 for Net@50, an event exploring the internet’s past and future.] No one has done more than Donald Norman to teach us that every piece of hardware … Continue reading “Ex-Apple UX Guru Don Norman Calls for Replacing the Internet”
What Is the Future of the Internet? Experts Predict Next 50 Years
[Editor’s note: This is part of a series examining the internet’s first 50 years and predicting the next half century. Join Xconomy and World Frontiers Forum on July 16 for Net@50, an event exploring the internet’s past and future.] It’s a good thing journalists, pundits, and consultants can’t be held liable for the predictions we … Continue reading “What Is the Future of the Internet? Experts Predict Next 50 Years”
What ARPANET’s History Can Teach Us About Cybersecurity
[Editor’s note: This is part of a series examining the internet’s first 50 years and predicting the next half century. Join Xconomy and World Frontiers Forum on July 16 for Net@50, an event exploring the internet’s past and future.] The internet nearly came with built-in caller ID. The year was 1972: three years after the … Continue reading “What ARPANET’s History Can Teach Us About Cybersecurity”
Peter Gabriel Joins Net@50 Lineup; Tix Going Fast for July 16 Event
Legendary rock musician and longtime internet evangelist Peter Gabriel has joined the all-star cast of speakers for Net@50, a historic event celebrating the 50th anniversary of the first net message—while also looking ahead to the internet’s next 50 years. The event, put on by the non-profit World Frontiers Forum in association with Xconomy, takes place … Continue reading “Peter Gabriel Joins Net@50 Lineup; Tix Going Fast for July 16 Event”
As Cities Ban Face Recognition, Body-Cam Firm Axon Also Nixes It
This week’s decision by police equipment manufacturer Axon to forego using facial recognition software in its body cameras follows a string of other actions against the use of face-matching technology by public agencies. They include a pioneering ban in San Francisco last month, and another passed Thursday by the city council of Somerville, MA. What … Continue reading “As Cities Ban Face Recognition, Body-Cam Firm Axon Also Nixes It”
Bio Roundup: Merger Drama, FDA Trauma, Big IPOs, CRISPR Fights & More
It was a busy week. If we had to choose a theme, it was all about getting together. Two huge drug companies, AbbVie and Allergan, said they’d be better as one. Two more huge drug companies, Celgene and Bristol-Myers Squibb, learned they would have to leave a big product behind if they want to merge. … Continue reading “Bio Roundup: Merger Drama, FDA Trauma, Big IPOs, CRISPR Fights & More”
Providence St. Joseph to Buy Wisconsin Health IT Consultant Bluetree
Providence St. Joseph Health, a large network of hospitals and clinics headquartered in Renton, WA, said Thursday it plans to acquire Bluetree Network, a consultancy that specializes in projects involving electronic health records software. Providence did not say how much it will pay to acquire Madison, WI-based Bluetree in a news release announcing the deal, … Continue reading “Providence St. Joseph to Buy Wisconsin Health IT Consultant Bluetree”
What’s Worth $34B? IBM Gets OK in Europe for Acquisition of Red Hat
IBM’s acquisition of open-source software maker Red Hat cleared the hurdle of approval from European regulators Thursday because it raised no concerns about competition, according to the European Commission. The $34 billion deal, which the companies plan on closing in the second half of 2019, drew attention when it was announced last fall for being … Continue reading “What’s Worth $34B? IBM Gets OK in Europe for Acquisition of Red Hat”
Degreed Raises $75M to Expand in Growing Workforce Training Sector
Degreed, which helps businesses upgrade the skills of their staffers through an online gateway to learning resources, announced Thursday it has raised $75 million to grow the service and expand internationally. San Francisco-based Degreed is among the educational technology companies now classified as “learning experience platforms,’’ because they organize staff participation in skills development training … Continue reading “Degreed Raises $75M to Expand in Growing Workforce Training Sector”
BridgeBio Upsizes IPO to $348M, Topping Adaptive’s Wall Street Debut
Rare disease drug developer BridgeBio is now a public company, raising $348.5 million in the biggest biotech IPO so far this year. On Wednesday night, BridgeBio priced its stock offering of 20.5 million shares at $17 each, topping the $14 to $16 per share price range it had initially targeted. The Palo Alto, CA, company … Continue reading “BridgeBio Upsizes IPO to $348M, Topping Adaptive’s Wall Street Debut”
Sequencing Firm Adaptive’s $300M IPO Comes With Pharma Ambitions
If biotech’s historic bull run is losing steam, as some observers believe, this week is one hell of a final stampede. Adaptive Biotechnologies of Seattle just raised $300 million. BridgeBio Pharma of Palo Alto, CA, has topped it, raising $348.5 million. Both begin trading Thursday. The combined haul is a remarkable sum, more than 2 … Continue reading “Sequencing Firm Adaptive’s $300M IPO Comes With Pharma Ambitions”
Led by Tech, Healthcare Debuts, IPOs in 2019 Show Positive Returns
Even as Uber, Lyft, and other high-profile initial public offerings underperformed out of the gate, the average share price of companies that have gone public in the US this year is up by almost 33 percent. That’s according to data based on the mean returns of issuers that started trading through June 19, released by … Continue reading “Led by Tech, Healthcare Debuts, IPOs in 2019 Show Positive Returns”
The Path to a More Human Voice Interface
The world is changing fast. Everything is getting connected. The connected home – the smart fridge, the smart thermostat, the smart TV – will soon be a mainstay of a connected world, an era quickly being ushered in by 5G, AI on the edge, and a slew of other enabling technologies. And I believe the … Continue reading “The Path to a More Human Voice Interface”
AbbVie to Pay $63B for Allergan to Prepare for Life Without Humira
[Updated, 10:11 am ET, see below.] Pharmaceutical giant AbbVie this morning agreed to acquire Allergan in a $63 billion deal meant to provide the pharmaceutical giant with enough revenue to brace for the loss of patent protection for the world’s top-selling drug. AbbVie (NYSE: [[ticker:ABBV]]) will pay $188.24 per share in cash and stock for … Continue reading “AbbVie to Pay $63B for Allergan to Prepare for Life Without Humira”
Dems and GOP Senators Unite Versus Big Tech on Data Privacy Bills
To hear some people talk, you’d think the age of bipartisan action in Congress was a lost phenomenon of the distant past. But it’s not so, at least when it comes to certain issues. And no one knows it better than the big Silicon Valley tech companies that are the recent targets of proposed bipartisan … Continue reading “Dems and GOP Senators Unite Versus Big Tech on Data Privacy Bills”
Review: Inside the House of Lies at Theranos
Youth. Charm. Fearlessness. Ruthless focus. These can be positive attributes in an entrepreneur, but in a more rational world, technology investors wouldn’t overvalue them. Risk capital would be allocated based mostly on evidence, data, progress towards milestones—in short, on proof. In the real world, of course, proof is hard to come by. Hope, avarice, or … Continue reading “Review: Inside the House of Lies at Theranos”
Bio Roundup: Array Bio Acquired, IPO Spree, Sanofi’s Job Cuts & More
[Corrected 6/24/19, 12:08 p.m. See below.] Cancer remains one of the hottest areas for pharma deals and this week saw a big one: Pfizer’s proposed $11.4 billion buyout of Array Biopharma. The announcement comes less than a month after Boulder, CO-based Array announced positive data from a pivotal study of its combination drug in colorectal … Continue reading “Bio Roundup: Array Bio Acquired, IPO Spree, Sanofi’s Job Cuts & More”
Four More Through the IPO Door as Life Science Firms Raise $465M
It’s been a strong year for biotech IPOs and Wednesday shaped up to be a particularly busy day as four life science firms debuted on the public markets. So far this year, 72 companies have gone public, according to IPO research firm Renaissance Capital. That total is down 20 percent compared to the same period … Continue reading “Four More Through the IPO Door as Life Science Firms Raise $465M”
Airbus Bets Microsoft Mixed Reality Will Boost Aircraft Production
Airbus, one of the world’s largest aircraft manufacturers, announced Monday it plans to ramp up production in coming decades with help from hologram-based virtual reality technology developed by Microsoft. Netherlands-based Airbus says it will equip some of its aircraft and equipment designers with HoloLens technology developed by Redmond, WA-based Microsoft (NASDAQ: [[ticker:MSFT]]). The HoloLens system … Continue reading “Airbus Bets Microsoft Mixed Reality Will Boost Aircraft Production”
Colorectal Cancer Data Spurs Pfizer to Pay $11.4B for Array Bio
[Updated 11:02 a.m. See below.] Array BioPharma touted data less than a month ago that could shift the treatment landscape for some patients with metastatic colorectal cancer. The data caught the eye of Pfizer, which just agreed this morning to buy the Boulder, CO, cancer drug maker for $11.4 billion. Pfizer (NYSE: [[ticker:PFE]]) will pay … Continue reading “Colorectal Cancer Data Spurs Pfizer to Pay $11.4B for Array Bio”
Bio Roundup: Roche-Spark Drags On, GSK Taps CRISPR, Diabetes News & More
Is one of the bigger biopharma acquisitions of the year in trouble? This past week, antitrust regulators once again delayed Roche’s planned $4.8 billion buyout of gene therapy developer Spark Therapeutics (NASDAQ: [[ticker:ONCE]]). The US Federal Trade Commission wants yet more information about the buyout, and overseas, the UK Competition and Markets Authority opened a … Continue reading “Bio Roundup: Roche-Spark Drags On, GSK Taps CRISPR, Diabetes News & More”
Gener8tor to Make Startups From Scratch in Revamped Milwaukee Program
[Updated 6/14/19, 10:25 am CT. See below.] Gener8tor, a Wisconsin-based organization with a growing network of startup accelerators across the Midwest, is shaking up the format of its flagship Milwaukee program in a bid to catalyze entrepreneurship among locals. Instead of seeking applications from existing startups located around the world, this fall’s Gener8tor program in … Continue reading “Gener8tor to Make Startups From Scratch in Revamped Milwaukee Program”
Your Tech Startup Is Probably Not Ready to Raise Money
I know, I don’t even know you. Here’s the thing. Let’s say Melanie is an early-stage investor. If she placed a bet blindly for every startup that thinks they’re ready to raise, her chips would fall on the “not ready to raise” words written in fancy script on the soft green felt of the betting … Continue reading “Your Tech Startup Is Probably Not Ready to Raise Money”
IPO Scorecard: CrowdStrike Gains 70 Percent on First Trading Day
Cybersecurity firm CrowdStrike delivered the kind of market debut this week that was an unfulfilled dream for the much-anticipated IPOs of Uber and Lyft earlier this year. Sunnyvale, CA-based CrowdStrike (NASDAQ: [[ticker:CRWD]]) priced 18 million shares of common stock at $34 on Tuesday. Trading began at $63.50 Wednesday, and reached a near-doubling of the company’s … Continue reading “IPO Scorecard: CrowdStrike Gains 70 Percent on First Trading Day”
Salesforce to Boost Analytics Suite With $15.7B Deal to Buy Tableau
[Updated 6/11/19 10:36 a.m. See below.] Salesforce is joining forces with Tableau Software, announcing Monday it plans to acquire Seattle-based Tableau in an all-stock deal valued at $15.7 billion. The transaction would combine one of the world’s largest and best known sales-focused software vendors, San Francisco-based Salesforce, with one of the leading vendors of data visualization … Continue reading “Salesforce to Boost Analytics Suite With $15.7B Deal to Buy Tableau”
3 Tips to Boost Security, Trust With Increasingly Remote Workforce
Employers are increasingly offering remote work options as a differentiator to attract top talent in today’s competitive hiring market. And, with modern technology at their fingertips, employees have come to expect a seamless working experience whether they’re home, in the office, or on the road. These new expectations, coupled with the increase of contract and … Continue reading “3 Tips to Boost Security, Trust With Increasingly Remote Workforce”
Bio Roundup: ASCO Wrap, Bluebird’s EU Tap, CRISPR Baby Risk & More
Welcome to conference week. That’s not an official moniker, but is there any busier time on the biopharma calendar? As the American Society of Clinical Oncology meeting wrapped up in Chicago, the annual BIO conference kicked off in Philadelphia, and a deep dive into diabetes begins today in San Francisco. With half the biopharma world, … Continue reading “Bio Roundup: ASCO Wrap, Bluebird’s EU Tap, CRISPR Baby Risk & More”
Grail’s Cook Steps Down, Former Juno Executive Bishop Named CEO
Grail CEO Jennifer Cook has stepped down from the cancer diagnostics developer and its board of directors. Menlo Park, CA-based Grail said Thursday that Cook left due to “family health reasons.” Hans Bishop, a Grail director since last August, was appointed Cook’s successor in the chief executive role. He will also remain on Grail’s board. … Continue reading “Grail’s Cook Steps Down, Former Juno Executive Bishop Named CEO”
Cerf, Kahn, Perlman, Hillis & More at Net@50: Get Tix to Historic Event
How did the internet arise to change the world—and where is it heading? Given the state of technology and society, what are the best ways to curtail the spread of misinformation (among other challenges) and the harm it can bring? At the World Frontiers Forum and Xconomy, we can’t promise to cover everything, but we … Continue reading “Cerf, Kahn, Perlman, Hillis & More at Net@50: Get Tix to Historic Event”
Carmera Scores Lear Partnership, Adds Ex-Waymo Exec to Advisory Team
The month of May was big for Carmera, a startup in New York City developing high-definition maps for use in autonomous vehicles. The company rolled out a new development partnership with auto supplier Lear, and it landed a big name advisor and investor with Shaun Stewart, the former chief business officer of self-driving technology business … Continue reading “Carmera Scores Lear Partnership, Adds Ex-Waymo Exec to Advisory Team”
ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More
The American Society of Clinical Oncology meeting in Chicago has wrapped up for another year. Last week, we featured two stories that you wouldn’t find at the ASCO frenzy: Immunotherapy’s lack of progress in treating breast cancer, and one woman’s risky bet of tens of millions of dollars from her personal fortune to speed drug … Continue reading “ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More”
Apple Touts New Privacy Moves as Antitrust Probes Loom for Big Tech
Both the House leadership and the Trump administration are preparing to challenge the power of Google, Facebook, and other big tech companies by launching antitrust investigations into their allegedly anticompetitive business practices, as the Washington Post detailed it this week. But the growing concern about the pervasive control of tech giants in arenas such as … Continue reading “Apple Touts New Privacy Moves as Antitrust Probes Loom for Big Tech”
Highspot Snags $60M to Help Sales Professionals Refine Their Pitches
Highspot, a startup developing collaborative software for sales and marketing teams at large companies, announced Tuesday it has raised $60 million from investors. San Francisco-based Iconiq Capital led the Series D funding round, and was joined by new investor Sapphire Ventures, Highspot says. Other participants included return backers Madrona Venture Group, OpenView, Shasta Ventures, and … Continue reading “Highspot Snags $60M to Help Sales Professionals Refine Their Pitches”
Eli Lilly’s Approved Migraine Drug Wins FDA OK for Cluster Headache
An Eli Lilly migraine drug that was approved last fall now has the regulatory nod to treat a rarer form of headache that tends to occur in clusters. The FDA on Tuesday approved the Lilly (NYSE: [[ticker:LLY]]) drug galcanezumab (Emgality) for episodic cluster headaches, which patients experience as one to four headaches per day, each … Continue reading “Eli Lilly’s Approved Migraine Drug Wins FDA OK for Cluster Headache”
Study: Gene Edits in CRISPR Babies Could Boost Risk of Earlier Death
The Chinese scientist He Jiankui, who revealed last fall that he used CRISPR gene editing to try to make twin newborn girls immune to HIV infection, might have also given them a higher risk of death. That’s according to a new study from University of California, Berkeley data scientists who analyzed the records of more … Continue reading “Study: Gene Edits in CRISPR Babies Could Boost Risk of Earlier Death”
LevelTen Energy Raises $20.5M to Facilitate Clean Power Purchases
LevelTen Energy, a startup that helps corporations make renewable energy purchases, has raised $20.5 million from investors. The Seattle-based company says it plans to use some of the new money to fund product development, make new hires, and expand into Europe. Prelude Ventures, a cleantech-focused venture firm based in San Francisco, led the Series B … Continue reading “LevelTen Energy Raises $20.5M to Facilitate Clean Power Purchases”
Seattle VC Watch: EndoGastric, Dolly, MDmetrix, SeekOut & More
Let’s catch up on some of the notable funding rounds raised by Seattle-area tech and life sciences companies in May: —EndoGastric Solutions, a Redmond-based business developing minimally invasive medical devices, said it raised $14.5 million from investors. EndoGastric’s devices treat gastroesophegeal reflux disease, which can cause chronic heartburn and injury to the esophageal lining. The … Continue reading “Seattle VC Watch: EndoGastric, Dolly, MDmetrix, SeekOut & More”